Breast Biopsy Market Expected to Reach $1,082 Million by 2030

According to a new report published by Allied Market Research, titled, “Breast Biopsy Market," The breast biopsy market was valued at $658.17 million in 2020, and is estimated to reach $1.1 Billion by 2030, growing at a CAGR of 5.1% from 2021 to 2030.

Breast biopsies are the tests that are used to detect area with an abnormal tissue growth or help in diagnosis of breast cancer. Defects and abnormalities in the cells can be detected with help of vacuum assisted biopsy, core needle, and fine needle biopsy. In addition, assisting the surgeons or radiologist to perform biopsy using specialized imaging equipment, such as ultrasound, mammography-guided stereotactic biopsy helps in advanced and better detection of cancerous or abnormal tissue and cell growth.

Breast biopsy is a medical technique that helps to examine the suspicious growth region of breast. It helps in diagnosis of irregular growth of cells and tissues in order to determine whether they are cancerous. It takes a sample of breast tissue to discover the growth of breast lumps & other abnormalities and helps in further observation of malignant behavior of cells. It is regarded as a reliable approach for cancer detection.

When a person is exposed to symptoms of sore breast, breast lump, breast dimpling, peeling of breast, and nipple discharge, they are recommended to opt for breast biopsy in comparison to invasive surgical procedures as invasive surgical procedures for breast biopsy have been found to be ineffective since they are uncomfortable.

The factors that surge the breast biopsy market growth are rise in concerns of mammary cancer in all countries, as well as awareness campaigns & screenings done in the favor of the hereditary gene BRCA1 and BRCA 2. Moreover, technological advancements and increased adaptive mammography-guided stereotactic biopsy are projected to provide a significant growth in the near future. Although, the market has benefited from the cultivating research environment, which has contributed in the development of more accurate and minimally invasive procedures for the early identification of mammary cancer. Governments have also tried to create a stable and comprehensive environment for cancer research, which has aided the development of these diagnostic technologies.

The pandemic had a number of negative consequences on breast biopsy market growth. Owing to lockdowns in several nations to prevent the spread of COVID-19, hospitals, clinics, and diagnostic facilities were unable to deliver biopsy services. With delay in treatments and priority of COVID diagnosis held the market to face a negative consequence. A relaxation in the pandemic situation enforced the hospitals to be focused on the delayed appointments, which helped the market regain its growth. Overall, COVID-19 initially had a negative impact on breast biopsy market however after relaxation in the situation and surge in regulatory approvals, the market possessed a positive impact.

The breast biopsy market size is segmented on the basis of product, image guided technology, end user, and region. On the basis of product, it is categorized into vacuum-assisted biopsy (VAB), core needle biopsy (CNB), and fine needle aspiration biopsy (FNAB). By image guided technology, it is classified into MRI-guided biopsy, ultrasound guided biopsy, mammography guided stereotactic biopsy, CT-guided biopsy, and others. On the basis of end user, it is bifurcated into clinic diagnostic centers and hospitals. Geographically, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Germany, Russia, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, Singapore, Philippines, and rest of Asia-Pacific), and LAMEA (Brazil, Turkey, Israel, Saudi Arabia, South Africa, and rest of LAMEA).

By product, the breast biopsy market size is divided into biopsy needles, guidance systems, biopsy tables, localization wires, assay kits, liquid biopsy instruments, and others. Based on type, breast biopsy market analysis include needle breast biopsy (core needle biopsy (CNB), fine-needle aspiration biopsy (FNAB), vacuum-assisted biopsy (VAB)), open surgical breast biopsy (excisional, incisional), liquid breast biopsy (circulating tumor cells, circulating tumor DNA (ctDNA), and other biomarkers.

On the basis of image guided technology, the market is fragmented into image-guided biopsy (mammography-guided stereotactic biopsy, ultrasound-guided biopsy, MRI-guided biopsy, other guidance techniques) and liquid biopsy (NGS-based Biopsy, PCR-based biopsy, microarray-based biopsy). In addition, breast biopsy has application across early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring.

Key Findings of the Study

• The study gives a top to bottom investigation of the breast biopsy industry, with most recent things and future appraisals to explain the imminent investment pockets.
• The breast biopsy market forecast is studied for a period of 2021 to 2030. 
• It gives a quantitative investigation from 2020 to 2030 to engage the accomplices to gain by prevailing market opportunities.
• Wide investigation by product type and end user determines the various trends and prevailing opportunities in the different market.
• Complete examination of all land regions is given, which assist with determining the main opportunities.
• Key market players are profiled and their strategies are investigated totally to expect the relentless standpoint of the market.

In 2020, North America held the major breast biopsy market share in terms of revenue, and the region is also projected to maintain its dominance over the forecast period from 2021 to 2030. Furthermore, Asia Pacific is anticipated to experience the fastest growth over the forecast period from 2021 to 2030. The rapidly developing economies of the region have invested in infrastructural development in the healthcare sector, which propels the market growth.